Plain-English translation of NCT06419374 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called to see if it can help people who have developed cirrhosis (severe scarring) of the liver due to metabolic dysfunction-associated steatohepatitis, commonly called fatty liver disease. Researchers want to know if this treatment can slow down or improve liver damage in people whose disease has reached an advanced stage but hasn't yet caused serious complications.
Fatty liver disease is becoming more common and currently has very limited treatment options. This trial exists to see if this medication can offer hope to people with advanced liver scarring, potentially preventing their condition from getting worse.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either or a placebo (a dummy medication) and visit the research site regularly for check-ups, blood tests, and monitoring. The trial will track how your liver disease progresses over time and watch carefully for any side effects. You'll be part of a study enrolling about 762 people to determine whether this medication actually helps people with advanced fatty liver disease.
AI-generated summary from trial data · Aug 19, 2026 · Not medical advice
United States